Get the Stockscreener App
16.23
0.61%
-0.10
After Hours:
16.30
0.07
+0.43%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $16.23, with a volume of 8.91M.
It is down -0.61% in the last 24 hours and down -0.18% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$16.33
Open:
$16.355
24h Volume:
8.91M
Relative Volume:
0.86
Market Cap:
$18.90B
Revenue:
$14.57B
Net Income/Loss:
$-296.50M
P/E Ratio:
-62.66
EPS:
-0.259
Net Cash Flow:
$1.64B
1W Performance:
+5.53%
1M Performance:
-0.18%
6M Performance:
+31.20%
1Y Performance:
+80.13%
1-Day Range:
$16.09
$16.52
1-Week Range:
$15.22
$16.52
52-Week Range:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.23 | 19.02B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
15.98 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.33 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.31 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
73.25 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
544.92 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Upgrade | UBS | Neutral → Buy |
| Jan-16-26 | Upgrade | Argus | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris' VR-205 Meets Primary, Key Secondary Endpoints in Japanese Phase 3 Trial in Kidney Disease - marketscreener.com
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - PR Newswire
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Join Class Action to Recover Losses from Viatris Inc. (VTRS)Contact Levi & Korsinsky Before June 3, 2025 - The National Law Review
Enterprise value to EBITDA forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com - Investing.com South Africa
Viatris interim CFO Paul Campbell sells $809,784 in stock - Investing.com UK
Form 4 Viatris Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Planned sale: Viatris (VTRS) officer disposes 50,076 shares - Stock Titan
Viatris | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Viatris, Inc. Actuals & Estimates (FWB:VIA) - TradingView
Price to sales forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris, Inc. Actuals & Estimates (SWB:VIA) - TradingView
Viatris, Inc. Actuals & Estimates (BMV:VTRS) - TradingView
Viatris Inc (VTRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Viatris, Inc. Actuals & Estimates (DUS:VIA) - TradingView
Form 144 Viatris Inc For: 25 June By Investing.com - Investing.com Nigeria
Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries - Stock Titan
VTRS Forecast — Price Target — Prediction for 2027 - TradingView
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
How Viatris’ €650 Million Eurobond Issue (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) - Seeking Alpha
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. (VTRS) Investor Outlook: Is The 15.89% Potential Upside Worth The Risk? - DirectorsTalk Interviews
Come As You Are: Emily Smith Builds Solidarity, Support for LGBTQ+ Colleagues Through VIVID - CSRwire
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Issues €650 Million Senior Notes to Refinance Debt - TipRanks
Viatris Completes €650 Million 4.250% Senior Notes Due 2033 to Refinance 2026 Debt - TradingView
Viatris (NASDAQ: VTRS) issues €650M 4.25% notes to help refinance 2026 debt - Stock Titan
(VTRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
XS332542958 Bond Price and Chart — FWB:XS332542958 - TradingView
Viatris Inc (VTRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viatris Inc (VTRS) Institutional Confidence - TradingKey
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris Recognized as One of the 2026 Best Workplaces™ in Canada - Yahoo Finance
Viatris Issues €650 Million Senior Notes in Europe - TipRanks
Viatris launches €650M 4.250% senior notes due 2033 offering - TradingView
Viatris (VTRS) prices €650M 4.250% senior notes maturing 2033 - Stock Titan
Viatris (VTRS) sells €650M 4.25% senior notes to refinance 2026 debt - Stock Titan
Euro Bond Sale Might Change The Case For Investing In Viatris (VTRS) - simplywall.st
Viatris Inc. (VTRS) Stock Analysis: Navigating Growth Prospects with an 8.09% Potential Upside - DirectorsTalk Interviews
Viatris (VTRS) Stock And The 58% Undervaluation Debate After A Strong Year Of Returns - Yahoo Finance
Viatris Euro Debt Raise Reshapes Capital Structure And Valuation Story - Yahoo Finance
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
3.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):